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This paper presents a systems approach to evaluating the potential of integrated continu-
ous bioprocessing for monoclonal antibody (mAb) manufacture across a product’s lifecycle
from preclinical to commercial manufacture. The economic, operational, and environmental
feasibility of alternative continuous manufacturing strategies were evaluated holistically
using a prototype UCL decisional tool that integrated process economics, discrete-event sim-
ulation, environmental impact analysis, operational risk analysis, and multiattribute
decision-making. The case study focused on comparing whole bioprocesses that used either
batch, continuous or a hybrid combination of batch and continuous technologies for cell cul-
ture, capture chromatography, and polishing chromatography steps. The cost of goods per
gram (COG/g), E-factor, and operational risk scores of each strategy were established
across a matrix of scenarios with differing combinations of clinical development phase and
company portfolio size. The tool outputs predict that the optimal strategy for early phase
production and small/medium-sized companies is the integrated continuous strategy (alter-
nating tangential flow filtration (ATF) perfusion, continuous capture, continuous polishing).
However, the top ranking strategy changes for commercial production and companies with
large portfolios to the hybrid strategy with fed-batch culture, continuous capture and batch
polishing from a COG/g perspective. The multiattribute decision-making analysis highlighted
that if the operational feasibility was considered more important than the economic benefits,
the hybrid strategy would be preferred for all company scales. Further considerations out-
side the scope of this work include the process development costs required to adopt continu-
ous processing. VC 2017 The Authors Biotechnology Progress published by Wiley
Periodicals, Inc. on behalf of American Institute of Chemical Engineers Biotechnol. Prog.,
000:000–000, 2017
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Introduction
A major challenge facing the biopharmaceutical industry
centers on how best to improve research and development
(R&D) productivity while reducing R&D and manufacturing
costs.1–4 Identification of strategies to reduce nonclinical
R&D costs can yield significant improvements in R&D pro-
ductivity given that they typically represent 20–30% of R&D
costs.5,6 Clinical manufacturing costs and process validation
batches account for a significant proportion of the nonclini-
cal R&D costs. Hence, biopharmaceutical engineers and sci-
entists are keen to explore ways to develop more cost-
effective and agile manufacturing processes while continuing
to meet product quality targets. Given the lengthy, complex,
and highly regulated nature of the development pathway for
biopharmaceutical drugs, the industry has been debating
which biopharmaceutical production technologies will facili-
tate industrialization of the sector.7–10
In recent years, continuous bioprocessing has seen a resur-
gence of interest related to its potential to challenge the
established position of the batch platform for the production
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of biopharmaceuticals such as monoclonal antibodies
(mAbs). As a result, several companies have been evaluating
continuous bioprocessing technologies11–14 to determine if
they can realize their potential benefits such as higher equip-
ment utilization rates, smaller facility footprints, reduced
cycle times, lower investment costs, and lower production
costs. Recent FDA strategic plans15 and Quality by Design
(QbD) initiatives appear to encourage such explorations of
continuous biomanufacture.
A holistic assessment of continuous bioprocessing
requires evaluation of the potential of integrated continuous
bioprocesses across multiple products moving through the
development pathway. This paper aims to achieve this by
developing and applying a prototype decisional tool to
address the following topical questions. Is there a business
case for continuous bioprocessing for early phase manufac-
ture? How does the business case change for commercial
multiproduct manufacture? Will tomorrow’s process be a
hybrid of batch and continuous technologies? This study
builds upon previous studies at UCL16–18 that explored the
batch versus continuous question initially for upstream
processing and then for capture chromatography. This paper
extends the analysis to integrated continuous bioprocesses
with consideration of the impact of both development phase
and company portfolio size. The insights from the deci-
sional tool will be illustrated through the use of industrial
case studies that provide economic, environmental and
operational perspectives on the decision to select batch ver-
sus continuous processes for clinical and commercial mAb
manufacture.
Background on perfusion culture and continuous
chromatography in bioprocessing
Perfusion Culture. Fed-batch cell culture has been estab-
lished as the platform choice for most mAbs in recent years
given the increase in fed-batch titres combined with their
ease of operation.7,19,20 Historically, the use of perfusion cul-
ture systems has been hampered by greater logistical and
validation complexity as well as higher likelihoods of techni-
cal failures.16,21,22 However, more recent perfusion culture
retention devices aim to overcome some of these obstacles
with the promise of higher productivities, lower failure rates,
and the ability to link to single-use bioreactors.16 The recent
performance trajectory of perfusion culture systems has
prompted renewed interest in their potential.
Pollock et al.16 provide a summary of the perfusion cul-
ture systems utilized by 12 commercial therapeutic biologics
that include recombinant blood factors, enzymes and mAbs.
Filtration-based retention devices in perfusion culture have
experienced a technology evolution from internal spin-filters
to external spin-filters and more recently to tangential flow
filtration (TFF) or alternating tangential flow filtration (ATF)
(Repligen Corporation, Waltham, MA) in an effort to mini-
mize filter fouling and avoid premature culture termination.23
These more recent retention devices are being employed in
the commercial production of mAbs (e.g., Simponi
VR
and
Stelara
VR
, Janssen Biotech).16 The ATF system achieves
media exchange by circulating the broth back and forth
between the bioreactor and an external hollow-fiber filter via
the action of a diaphragm pump.24,25 As a result, the ATF
perfusion system enables reduced filter fouling instances and
consequences and higher cell densities and hence productiv-
ities compared to earlier perfusion systems.
On the process economics front, there are few contribu-
tions that examine the economic feasibility of filtration-
based perfusion culture systems. Lim et al.21,22 compared a
spin-filter perfusion to a fed-batch strategy under uncertainty,
for a mAb output of 50 kg/year and a titre of 1 g/L. The
authors used a stochastic analysis to demonstrate the reduc-
tion required in the failure rate of the spin-filter perfusion
strategy for it to compete with the fed-batch strategy at this
scale. Pollock et al.16 presented a cost of goods comparison
of fed-batch strategies to first generation (spin-filter) and sec-
ond generation (alternating tangential flow filtration, ATF)
perfusion systems for the commercial manufacture of mAbs
in dedicated facilities. The case study explores the impact of
a number of key factors: (a) single-use bioreactors and scale
of production on costs, (b) equipment failure rates on robust-
ness, and (c) qualitative concerns (e.g., ease of development)
on the technology rankings. The authors illustrate how the
economic competitiveness of whole bioprocesses employing
perfusion culture processes depends on the cell density
increase achievable with perfusion and the equipment failure
rates compared to fed-batch strategies. The tool’s predictions
that the spin-filter perfusion strategy struggles to compete on
economic, environmental, operational, and robustness fronts
at most titres and scales provides insight into its limited use
in industrial processes. In contrast the ATF perfusion strat-
egy was predicted to offer economic benefits that outweigh
its lower robustness for cases with peak cell densities that
are at least threefold higher than in fed-batch for scenarios
of commercial production in dedicated facilities.
Semicontinuous Chromatography. The current and future
mAb purification platforms rely on a series of orthogonal
chromatography steps with Protein A as the preferred pri-
mary capture step.8,19,20,26 Protein A resins represent the
leading material cost contributor in most platforms.16,17 For
manufacture of early phase material, Protein A resin can
account for 50% of the direct costs; however, during com-
mercial manufacture, it contributes typically to 10% of the
direct costs.17 During clinical manufacture, product-specific
chromatography resins are often used for just a few cycles
and then discarded particularly if the drug candidate is
unsuccessful. As a result the resins do not realize their full
potential cycle lifetime. This is a particular concern in mAb
development and improving utilization of these expensive
resins can have a significant effect on the (pre)clinical
manufacturing costs by reducing the cost burden associated
with failed drug candidates.
Semicontinuous chromatography has been shown to be an
effective way to increase resin utilization and hence reduce
resin volumes required by 40–50%, step buffer consumption
by 40–50% and overall process buffer consumption by 12–
15%.11,12,16 Different continuous chromatography technolo-
gies currently available from vendors include the periodic
counter current (PCC) system (3–4 columns) from GE
Healthcare (Uppsala, Sweden), BioSMB (6–12 columns)
from Pall Life Sciences (Port Washington, NY), BioSC (2–6
columns) from Novasep (Pompey, France), and SMBC (4–
8 columns) from Semba Biosciences (Madison, WI). These
systems increase utilization by dividing a standard batch col-
umn into multiple portions. This allows the first column to
be loaded to 100% breakthrough while redirecting the flow-
through onto the next column to capture the target. This
makes use of what would usually be unsaturated capacity in
a standard single-column chromatography system. Several
biopharmaceutical manufacturers have been actively
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evaluating these technologies. For example, GE’s PCC sys-
tem has been reported to be evaluated by Amgen,27 Cento-
cor/Janssen,28 Genentech,11 Genzyme,12,13 and Pfizer/UCL,17
while Pall’s (previously Tarpon’s) BioSMB system has been
reported to be investigated by Bayer,29 Biogen-Idec,30
Merck,14 and Pfizer.31
Financial implications of adopting continuous chromatogra-
phy have been presented by Pollock et al.17 The study explores
the potential of continuous capture chromatography to reduce
clinical and commercial mAb manufacturing costs. The tech-
nology evaluation integrated small-scale experimentation, which
was verified with a continuous system in operation, with simu-
lation assessment. The authors illustrate that whole bioprocesses
that utilize continuous chromatography for product capture
have the ability to offer significant direct cost savings in early
clinical phase material generation; this can have a large impact
considering the high clinical attrition rates.
Integrated Continuous Bioprocesses. Recent papers have
detailed successful implementation of integrated, closed, and
continuous bioprocesses linking an alternating tangential
flow perfusion process to two semicontinuous chromatogra-
phy steps for capture and polishing.12,13 Results have been
illustrated for the production of both stable (mAb) and less
stable (enzyme) proteins in an uninterrupted manner over
extended periods with consistent time-based system perfor-
mance and product quality. Such examples act as important
proof-of-concept demonstrations for the sector of the poten-
tial of integrated continuous bioprocesses.
This paper scopes out a vision for a number of integrated
continuous manufacturing processes and utilizes a decisional
tool to provide novel insights on the suitability of these
future manufacturing strategies across a matrix of industry
scenarios. The paper presents a framework for evaluating
integrated continuous processes rather than stepwise compar-
isons carried out in previous work. The analysis is extended
to derive and incorporate operational risk scores considering
the adoption of continuous technologies. These scores are
combined with the calculated economic and environmental
performance metrics so as to give an overall manufacturing
strategy ranking. The impact of both development phase and
company size is explored on the optimal manufacturing strat-
egy in terms of batch and continuous unit operations. In all
scenarios, the models spanned the whole bioprocess from
cell culture through to polishing so as to capture the full
impact of any upstream or downstream choice on the overall
process economics and the impact of multiproduct facilities
explored at each phase of development.
Methods
Visualising an integrated continuous process
A key concept of an integrated continuous process is that
continuous, steady-state processing extends from the bioreac-
tor to the final purification operation. However, this concept
is currently not possible in biopharmaceutical manufacture
due to the lack of suitable technology and strict regulatory
requirements. Continuous perfusion bioreactors for example
do generate a continuous stream of harvested cell culture
fluid (HCCF), but they can only achieve this in a batch oper-
ation. First, the cell culture has to reach the desired steady-
state cell density to achieve a constant concentration of
HCCF and then can only produce a continuous stream of
HCCF for a defined period, before a new cell culture batch
is required. This semicontinuous mode of operation is also
found in the search for continuous downstream processing
operations where chromatography systems that are described
as continuous are capable of continual loading but only gen-
erate discrete elution pools of product. The challenge is fur-
ther complicated by the stringent quality and regulatory
requirements that dominate biopharmaceutical manufacture.
The ability of the manufacturing process to demonstrate viral
clearance is critical, with a mandatory inclusion of two dedi-
cated viral clearance operations (viral inactivation and viral
retention filtration). Both of these operations are currently
achieved in a batch operation; for example, in a viral inacti-
vation step the product stream is held at a low pH for a
defined period of time, before processing continues. A fur-
ther regulatory complication is batch traceability, a key area
of debate surrounding continuous processing, with the princi-
pal concern being “how do you define a batch?.”
These factors highlight how continuous processing is not
currently possible in biopharmaceutical manufacture. How-
ever, the use of semicontinuous unit operations can lead to a
semicontinuous manufacturing process, potentially capturing
some of the economic advantages seen in continuous proc-
essing. The upstream can be operated in a semicontinuous
manner by using perfusion culture, which is fed and bled at
a constant rate to generate a constant stream of HCCF when
steady-state cell density is achieved. The downstream is
more complicated due to the number of orthogonal purifica-
tion operations. The initial capture of the product from
HCCF can be achieved in a continuous manner, using semi-
continuous chromatography. The resulting process stream is
now being created in discrete elution volumes, which can
either be pooled into larger volumes or processed individu-
ally before moving to the subsequent purification steps.
These subbatches can be processed in the conventional batch
manner for the remaining purification steps or can be proc-
essed in a continuous manner.
Figure 1a shows the downstream scheduling for a typical
process sequence operated in batch mode, where each step is
Figure 1. Downstream process scheduling for (a) the base case
process sequence, (b) the continuous to batch process
sequence, and (c) the continuous process sequence.
Protein A, Protein A chromatography; VI, viral inactivation;
AEX, anion exchange chromatography; VRF, viral retention fil-
tration; UFDF, ultrafiltration/diafiltration.
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completed before the product stream is passed to the next.
Figure 1b shows an adapted process sequence where HCCF is
continually loaded onto a semicontinuous chromatography
step and the resulting elution volumes are pooled into larger
volumes before proceeding in a batch manner similar to Fig-
ure 1a for the remaining purification steps. Figure 1c demon-
strates a flow-sheet that operates the anion-exchange (AEX)
chromatography step and virus retention filtration (VRF) step
in a continuous manner. The product stream flows through the
AEX chromatography column and straight into the VRF step.
The VRF unit would be sized by calculating the filter area
capable of matching the volumetric flowrate from the AEX
chromatography step while maintaining the same transmem-
brane flowrate (20 LMH (Lm22 h21)) seen in the batch pro-
cesses (Figures 1a,b). Both process flowsheets operating the
semicontinuous chromatography capture step collect all the
processed subbatches (post VRF) into one final batch prior to
the final diafiltration step. This pooling approach helps solve
the regulatory requirement for batch traceability, by defining
the batch as all the material created in one fermentation run.
This approach also reduces the quality burden by reducing the
number of batch releases for a given manufacturing strategy.
Table 1 demonstrates how this concept results in five different
manufacturing strategies, where the capture step is defined by
the mode of Protein A chromatography used and the polishing
steps (AEX and VRF) are defined by how the resulting purifi-
cation steps are operated. The base case strategy employs a
fed-batch reactor generating a single discrete batch, which is
purified in a batch manner (Figure 1a). Similarly the fed-
batch, continuous capture and batch polishing (FB-CB) strat-
egy also employs a fed-batch reactor, but the ensuing batch is
purified using semicontinuous chromatography in a 72 h win-
dow with the polishing steps operated in the batch manner
(Figure 1b). In contrast, the ATF perfusion, continuous cap-
ture and batch polishing (ATF-CB) strategy employs an alter-
nating tangential flow (ATF) perfusion reactor to generate a
constant stream of HCCF which is captured directly onto the
semicontinuous chromatography step for the duration of the
perfusion run, prior to batch operated polishing steps. The
remaining strategies (FB-CC; Fed-batch, continuous capture,
continuous polishing, and ATF-CC; ATF perfusion, continu-
ous capture, continuous polishing) both employ a continuous
capture step that generates discrete subbatches, which are
pooled and then processed in a continuous manner in the pol-
ishing purification steps as shown in Figure 1c.
Decisional tool description
To successfully evaluate batch and semicontinuous bio-
pharmaceutical unit operations, a decisional tool (Pollock
et al., 2013a and 2013b)16,17 was created that captured the
operational, economic, environmental, and risk features asso-
ciated with each strategy. The decisional tool integrated
models on mass balancing, equipment sizing, bioprocess eco-
nomics, scheduling, uncertainty analysis, and multiattribute
decision-making. The tool was built in a discrete-event simu-
lation environment (Extend v6, Imagine That! Inc., San Jose,
CA). This permitted the dynamic consequences of resource
constraints, delays, uncertainties, and equipment failures to
be modeled in a temporal fashion and their impact on the
key metrics to be computed. The tool was database-driven
(MySQL AB, Uppsala, Sweden) so as to facilitate the speci-
fication of processes and better manage the large input and
output datasets required for multiple processes, uncertainty
analysis and optimization. The tool incorporated specific fea-
tures to capture the dynamics of continuous manufacture.
These included scheduling features of perfusion culture
related to interactions between the generation of daily perfu-
sion harvests and the subsequent pooling and purification
operations as well as the scheduling consequences of failure
events occurring at random times during the perfusion cul-
tures.16 The models for the continuous chromatography oper-
ations captured the experimentally derived design logic to
generate the optimal system scale and operating parameters
(e.g., switch time between columns).17
A precalculation and optimization module was created to
run prior to the simulation of a particular scenario so as to
assess all the possible equipment sizing strategies before
selecting the optimum process configuration (e.g., 1x 6000 L
versus 3x 2000 L bioreactors) for the given demand in terms
of both production time and cost. Alongside equipment scal-
ing the precalculation module also evaluated whether single-
use technologies could be implemented in the form of
single-use bioreactors and product holding bags, based on
the process volumes generated and utilized by each unit
operation.
The key economic metrics calculated by the tool were the
capital investment and the cost of goods per gram (COG/g)
for the complete manufacturing process (fermentation to
bulk drug substance), as well as the manufacturing cost per
launch (preclinical, clinical, process validation batches). The
capital investment was determined using the Lang factor
method as a function of the total equipment purchase cost.
The COG/g comprised the annual direct (materials and
labor) and indirect (depreciation and facility-dependent over-
heads) operating costs divided by the annual product output
as detailed in Farid et al.32 The key environmental metric
calculated by the tool was the E-factor,33 defined as the total
mass of water or consumables used by the manufacturing
strategy divided by the total mass of product. The tool’s
quantitative outputs were combined with qualitative opera-
tional metrics using a multiattribute decision-making
(MADM) technique,34 as described in the next section.
Multiattribute decision-making methodology
The weighted sum method provides a systematic mecha-
nism for explicitly capturing qualitative and nonfinancial per-
formance indicators in the evaluation. Its use has been
illustrated in several fields including bioprocessing16,35,36
where alternatives were evaluated against a set of attributes
that are typically considered intangible and conflicting. In
this paper, the economic, environmental, and operational out-
puts were reconciled using the weighted sum method so as
to identify the most attractive manufacturing strategy across
a range of scenarios, with different weightings assigned to
each of these categories. Table 2 lists all the attributes
Table 1. Mode of Operation for Key Stages of the Alternative Batch,
Continuous, and Hybrid Manufacturing Strategies
Manufacturing
Strategies USP Capture Polishing
Base case Fed-batch Batch Batch
FB-CB Fed-batch Continuous Batch
ATF-CB ATF perfusion Continuous Batch
FB-CC Fed-batch Continuous Continuous
ATF-CC ATF perfusion Continuous Continuous
Note: USP refers to upstream processing.
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considered in the MADM analysis. The simulation tool was
used to derive the economic and environmental attribute val-
ues. The attributes were ranked in order of importance,
where a ranking of one indicates an attribute of greater sig-
nificance. For example in the large-sized company the cost
per launch is more important than the commercial COG/g
and the initial capital investment required in facility con-
struction. In contrast the small-sized company ranks the ini-
tial capital expenditure the highest, highlighting the differing
financial philosophies found with company size. A large-
sized company’s main aim is to reduce the cash outlay for a
new drug and produce this material as cost-effectively as
possible. In contrast, the small-sized company will have
fewer resources to invest (facilities & drug development)
and will therefore want to minimize these costs before look-
ing to alternative funding sources upon product launch
(licensing, partnerships, mergers, and acquisitions). The
attributes representing the environmental feasibility were
ranked equally because the environmental impact of water
and consumable usage was deemed to be equally disadvanta-
geous to the environment. The operational feasibility was
represented by a risk score, which assesses the manufactur-
ing strategies perceived robustness (likelihood of batch
failure).
All attribute values were standardized37,38 to convert them
to a common dimensionless scale between 0 and 100. The
relative importance of the total weighted economic, environ-
mental, operational scores in the decision-making process
was captured using a set of combination ratios (dimension-
less weight values) whose sum equals one.37 The overall
aggregate strategy score Sj is generated by the weighted sum
method, using the following equation:
Sj5

Pn
i51 rijeconomic
n
3R1
1

Xn
i51
rijenvironmental
n
3R2

1

Xn
i51
rijoperational
n
3R3

(1)
where rijecononmic, rijenvironmental, rijoperational represent the
weighted scores for the economic, environmental and opera-
tional groups respectively (prior to combination) and R1, R2,
and R3 represent the economic, environmental, and opera-
tional combination ratios, respectively.
Case study assumptions
The decision-support framework was used to compare the
cost-effectiveness of the five alternative manufacturing strat-
egies throughout the development pipeline for a range of
company sizes, exploring the trade-offs between reduced
equipment scales versus increased manufacturing risk. Table
3 illustrates the clinical trials estimates used throughout this
case study to calculate the amount of mAb required for each
phase of the development pipeline. The earliest development
phase captured in this case study is the Pre-Clinical phase
where material is required for nonprimate animal model
studies. Assuming the average nonprimate (Macca Mulatta)
body weight is 8 kg39 and the study includes 110 nonpri-
mates (25% control group),40 a single 0.5 kg batch of mAb
is required for the Pre-Clinical development studies. The
case study then uses the quick win, fail fast clinical develop-
ment paradigm,4 where the material required for Phases I
and II is generated in a single batch for the Proof-of-
Concept (PoC) development phase. The average body weight
of a US male was presumed to be 86 kg41 and therefore a
single 4 kg batch of mAb would be required for PoC devel-
opment also accounting for nonclinical uses. This amount
increases to 40 kg of mAb for the phase III clinical trials
and is produced by four 10 kg batches at the Commercial
batch scale allowing parallel process validation studies. The
10 kg Commercial batch size is based on the median market
demand of the top 15 mAb (200 kg)8 and the ability to pro-
cess 20 batches per year in a typical fed-batch scenario. The
Table 2. Attribute Grouping and Weighting for Each Company Scale for the Multiattribute Decision-Making
Attribute Group Attribute Name Large Medium Small
Economic feasibility Manufacturing cost per launch 1 1 2
Commercial COG/g 2 2 3
Capital expenditure 3 2 1
Environmental feasibility Water E-factor 1 1 1
Consumable E-factor 1 1 1
Operational feasibility Batch risk 1 1 1
Note: Rank of 1 refers to most important attribute and 3 to the lowest.
Table 3. Key Assumptions for the Alternative Batch, Continuous,
and Hybrid Manufacturing Strategies
Variable Values
Clinical Trial Estimates
Non-human primate dosage (mg/kg body weight) 700
Non-human primate in Pre-Clinical trial 100
Patient dosage (mg/kg body weight) 7
Number of doses per patient per year 26
Individuals in Phase I clinical trials (single dose) 40
Individuals in Phase II clinical trials (6 month dose) 200
Individuals in Phase III clinical trials (year dose) 2,000
USP Process Parameters Fed-batch ATF
Cell culture time (days) 12 28
Harvest volumes 1 20
Max VCD (million cells/mL) 10 50
Max bioreactor volume (L) 20,000 1,500
Annual number of batches 20 10
DSP Process Parameters Batch PCC
Binding capacity (g/L) 40 65
Bed height (m) 0.25 0.1
Number of columns 1 3
Shift duration (hours) 12 24
Cost Parameters
QCQA batch release costs ($/batch) 35,000
Media cost ($/L) 3.1
Protein A resin cost ($/L) 8,000
AEX resin cost ($/L) 1,500
Virus retention filtration membrane ($/m2) 3,250
Labour cost ($/h) 58
Chromatography process skid (15–600 L/h) ($) 226,000
PCC process skid (15–600 L/h) ($) 1,080,000
Chromatography column (Dia 5 0.2 m) ($) 132,000
Chromatography column (Dia 5 2 m) ($) 218,000
Note: USP refers to upstream processing, DSP to downstream
processing.
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cell culture titre also increases with clinical phase, where
due to continued process development the titre was assumed
to increase twofold from the PoC batch to the Phase III and
Commercial batches. The scenario produced a 2.5 g/L titre
for the minimally developed Pre-Clinical and PoC batch
before increasing to a final titre of 5 g/L.
The base case manufacturing strategy used in the case
study was based on a generic two-column mAb process.7,42
The principal differences between the batch and semicontin-
uous unit operations are highlighted in Table 3. The key dif-
ference between the cell culture technologies is the length of
culture, where a fed-batch fermentation lasts 12 days allow-
ing 20 batches to be processed a year from a single reactor.
In contrast perfusion cell cultures can be run for much lon-
ger, however in this case study a culture duration of 28 days
was selected, making an annual throughput of 10 batches
possible. The 28-day perfusion length was selected over lon-
ger lengths considering issues such as the time required for
process validation or process performance qualification (PV/
PPQ) batches as well as the ability to fit in more products
per year. The perfusion-based options were sized to yield the
same kg outputs per phase with a view to keeping the scale
constant between Phase III and Commercial stages as in the
fed-batch case. Hence, for example, Phase III or Commercial
scenarios requiring greater than 10 3 10 kg perfusion
batches per year would result in numbering up to multiple
production lines. The semicontinuous PCC system utilizes
three smaller columns compared to the batch system, these
are loaded to 100% saturation increasing the binding capac-
ity from 40 to 65 g of mAb per liter of resin. To achieve the
higher productivity the PCC system must be operated contin-
uously requiring a 24 h manufacturing shift.
Table 4 highlights the major differences between different
sized companies with respect to the number of drug candi-
dates (DC) at any given stage of the drug development pipe-
line. A large company has been defined as a company that
aims to launch two new products per year. To achieve this
level of success 20 new DC’s must enter Pre-Clinical trials,
due to the high attrition rates seen in clinical development.
The medium-sized company aims to launch one product a
year and therefore requires 10 DC’s entering Pre-Clinical tri-
als per year. A small-sized company that aims to launch a
new product every 2 years requires only 5 DC’s in Pre-
Clinical trials per year.
Results and Discussion
The decision-support framework was used to assess the cost-
effectiveness of five manufacturing strategies with different
combinations of batch and continuous operations for cell cul-
ture, capture, and polishing steps throughout the drug develop-
ment pipeline. This was initially carried out by determining the
direct (labor, media, buffers, chromatographic resin, filter mem-
branes, QCQA batch release costs, etc.) and indirect (deprecia-
tion and facility-dependent overheads) costs. These were used
to establish the cost of goods per gram across combinations of
different development phases (Pre-Clinical through to Commer-
cial production) and company sizes (small, medium, and large).
Each development phase required different manufacturing
scales, batch numbers and material reuse strategies, and each
company size resulted in different numbers of drug candidates
at each development phase. The economic outputs were then
considered alongside operational and environmental metrics
using a multiattribute decision-making technique for all the
company sizes investigated.
Impact of development phase on cost drivers
Figure 2 shows the individual cost components per prod-
uct per phase as well as per gram for the base case batch
scenario for each manufacturing scales in the development
pipeline (0.5, 4, 40, and 200 kg) for a medium-sized com-
pany. Figure 2a highlights that as expected the costs of
chemicals (media, buffer) and single-use components (e.g.,
filters, bags) increase per product across the development
phases in proportion to the kg and batch output. Hence, the
cost per gram for chemicals and single-use components
remain relatively constant in Figure 2b as is typical for
Table 4. Number of Drug Candidates Per Company Scale Scenario
Company Size Pre-Clinical PoC Phase III Commercial
Large 20 14 4 2
Medium 10 7 2 1
Small 5 3 1 1*
*One successful launch every 2 years.
Figure 2. Direct cost of goods category breakdown across the
different manufacturing scales required for each
development phase for the base case scenario shown
as (a) direct cost per product per phase and (b)
direct cost per gram.
Categories: labor costs (gray dashed line), QCQA batch release
costs (gray solid line), chromatographic resin costs (black solid
line), fermentation media (black dotted line), and single-use
components and buffers (black dashed line).
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variable costs. The resin costs also increase as the
manufacturing scale increases across the development phases
but in contrast to the other cost categories, the resin cost
decreases at the Commercial scale of production. The
requirement to keep the resins product-specific, results in a
high cost burden per batch in early development phases,
because the resin is often discarded before reaching its full
potential cycle lifetime. The early manufacturing scales (Pre-
Clinical and PoC) only use the resin to purify a single batch
of material and therefore the resin purchase cost accounts for
over 80% of the material costs per batch. The later
manufacturing scales (Phase III and Commercial) use the
resin to purify multiple batches of material and therefore
reduce the cost impact of the expensive resin as reflected in
Figure 2b. The resin accounts for approximately 67% of the
Phase III material costs and 29% of the Commercial material
costs. Both manufacturing scales utilize the same sized col-
umns but only the Commercial scale uses the resin until its
full lifetime and therefore the resin cost is spread over multi-
ple batches and reduces the related resin costs shown.
The labor and QCQA costs are scale-independent and rise
in proportion to the increase in number of batches required
per product across the development phases rather than the kg
output (Figure 2a). As a result, their cost per gram values
decrease with kg output (Figure 2b). Finally the indirect
costs increase across the development phases in proportion
to the increase in batch size and hence facility size. Figure 3
demonstrates as expected that the indirect cost per gram
becomes less significant in the late clinical and Commercial
phases since the costs are spread over more batches.
Impact of company size on indirect costs
Table 4 highlighted the difference in drug candidate
throughput for each company size throughout the develop-
ment pipeline. The difference in drug candidate throughput
will affect the utilization of the manufacturing suites and in
turn impact the resulting manufacturing costs. Table 5 high-
lights the effect of company size on key indirect costs for
the base case scenario at the PoC scale of manufacture. The
capital expenditure required to construct the facility to gener-
ate a 4 kg PoC batch is the same for all the company sizes,
however the resulting batch suite cost and indirect cost per
gram is dependent on the batch throughput. The large-sized
company has the highest batch throughput with 14 drug can-
didates being processed a year resulting in an utilization rate
of 70% and a batch suite cost of $292k. In contrast the
small-sized company has a batch throughput of three drug
candidates resulting in a batch suite cost ($1,364k) that is
4.5-fold higher relative to the large-sized company.
Batch versus continuous COG/g comparison
Figure 4 shows the COG/g breakdowns for the base case
batch strategy and fully continuous strategy (ATF-CC) for
the medium-sized company. The analysis highlights that the
Pre-Clinical batch costs are dominated by indirect costs for
the base case and direct costs for the continuous strategy.
The larger equipment sizes seen in batch processing lead to
a higher batch suite cost of $255K per batch versus $120K
per batch for the smaller highly utilized continuous equip-
ment. However, the continuous operation requires significant
labor resources to support the continuous manufacturing
operations that require a 24 h manufacturing shift and there-
fore this increases the overall direct costs.
The base case is still dominated by indirect costs in the
later manufacturing scales in the development pipeline (PoC,
Phase III, and Commercial). For example, the Phase III
COG/g is dominated (70% of COG/g) by the batch suite cost
(indirect costs), due to the costs only being spread over four
batches in a commercial GMP facility. The continuous strat-
egy sees a shift from the direct to indirect costs dominating
COG/g for the later manufacturing scales. However, the
labor costs still account for a third of the COG/g. Tradition-
ally the direct costs are expected to dominate with an
increase in kg output, however, due to the relatively low kg
output in this scenario (200 kg) the indirect costs continue to
dominate COG/g. The indirect COG/g does decrease in sig-
nificance with increasing company size with direct costs
starting to dominate as kg output increases (large com-
pany—2 3 200 kg products).
The smaller batch sizes seen earlier in the development
pipeline have higher direct manufacturing costs per gram
because some of the costs are scale independent. For exam-
ple the QCQA batch release costs ($35,000) are constant
between a Pre-Clinical and Commercial batch, but due to the
difference in kg output (0.5–200 kg) the batch strategies Pre-
Clinical QCQA cost per gram is $73/g compared to $3.4/g
for the Commercial manufacturing scale. The same trend is
seen in the batch strategys labour costs which accounts for
nearly half the Pre-Clinical direct manufacturing costs at
$128/g compared to the Commercial manufacturing scale
with labour costs of $6/g. The overall percentage of direct
costs increases for the Commercial manufacturing of the
Figure 3. Direct (black dashed line) and indirect (black line)
cost of goods per gram across the different
manufacturing scales required for each development
phase for the base case scenario.
Table 5. Effect of Company Size on Indirect Cost Per Gram for the Base Case Scenario at the PoC (4 kg) Manufacturing Scale
Company Size Capital Expenditure (million $) Batch Suite Cost ($/batch) Indirect Cost/g ($/g)
Large 37.6 292,300 71
Medium 37.6 584,600 141
Small 37.6 1,364,000 330
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batch strategy, even with the real decrease in direct costs per
gram. This is due to the significant drop seen in batch suite
costs, from the Phase III ($600K per batch) to Commercial
($240K per batch) manufacturing scale.
For the medium-sized company, the tool outputs predict
that the integrated continuous ATF-CC strategy offers cost
savings for Pre-Clinical and Clinical production, but
becomes less economically attractive at the Commercial
scale. This is due to the requirement for a second
manufacturing production line given the kg output per batch
being matched to the Phase III requirement (10 kg) and max-
imum number of batches per year,10 resulting in the duplica-
tion of equipment (USP and DSP). The higher utilization
rate of the GMP facility at this manufacturing scale is
expected to lead to a significant reduction in indirect costs
(as shown by the batch strategy). However, the extra equip-
ment required for the additional production line means the
reduction is not fully realized and with the significant labour
requirements seen in the continuous strategy, the strategy is
no longer able to offer an economically attractive COG/g as
the batch scenario.
Key economic metrics across company size and
manufacturing scale
The impact of both manufacturing scale (Pre-Clinical,
PoC, Phase III, Commercial) and company size (small,
medium, large) on the competiveness of the five alternative
manufacturing strategies was investigated. The contour plots
in Figures 5a–c show the percentage difference in cost of
goods per gram relative to the base case strategy.
Figure 5 highlights that the ATF perfusion-based
manufacturing strategies are not able to compete with the
fed-batch strategies at the Commercial scale of manufacture
regardless of company size. The difference is most pro-
nounced for the large-sized company (Figure 5a), where the
high drug candidate throughput in the development pipeline,
results in the need to manufacture two commercialized prod-
ucts in a year. The ATF perfusion strategies are only able to
generate 10 batches per year per production line and there-
fore require four parallel perfusion reactors with dedicated
purification trains to meet the 40 batch annual demand. The
resulting facilities are approximately twice as expensive as
the corresponding fed-batch based facilities, which employ
two staggered reactors utilising a single larger purification
train. This effect is also seen for the medium and small-
sized companies (Figures 5b, 5c) where two production lines
are required to manufacture 20 batches of a single success-
fully commercialized product. The resulting Commercial
facilities are comparable in cost to the fed-batch based facili-
ties and offer the same level of capital expenditure saving
(25%) versus the base case due to the use of a smaller
purification train offered by the continuous capture step. Fig-
ures 5 and 6a highlight that the inability of the ATF perfu-
sion strategies to utilize a single production line for
Commercial manufacture, results in the fed-batch based
strategy FB-CB being the most economically attractive Com-
mercial manufacturing strategy for all company sizes.
Figure 4. A comparison of the direct costs per gram for the base case batch strategy (B) and fully continuous strategy (C) on a cate-
gory basis for material costs (black), labor costs (light gray), QCQA batch release costs (dark gray), and indirect costs
(white), between the different manufacturing scales.
The embedded table highlights the percentage cost contribution for the key direct cost categories.
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Figure 5 highlights that the FB-CB manufacturing strategy
is the most consistent strategy, offering COG/g savings at all
manufacturing and company scales relative to the base case.
This is possible due to the continuous capture step which
reduces the volume of expensive Protein A resin required
and generates a more concentrated elution pool allowing a
smaller purification train to be employed, reducing both
direct and indirect batch costs. However, the FB-CB does
not offer the highest level of savings for product develop-
ment stages, as highlighted in Figure 6a that shows the top
ranking strategies across the different manufacturing and
company scales. Instead, this is achieved by the ATF-CB
and ATF-CC manufacturing strategy, depending on the phase
of development. The ATF-CB strategy offers superior COG/
g savings during clinical manufacture because it is able to
reduce the size of the purification train even further by the
continuous generation of small volumes of HCCF. This has
a significant impact on the dominant material costs by
replacing the resin cost with media cost, due to the 10-fold
reduction in column volume and the fourfold increase in fer-
mentation media use. The FB-CC and ATF-CC also reduce
the scale of the purification train they employ, however, the
continuous polishing steps result in the suboptimal scaling of
the virus retention filtration operation. The batch-operated
polishing process strategies operate the virus retention filtra-
tion step for a complete 10 h shift, whereas continuous-
operated polishing process strategies run the operation for
the shorter duration (2–3 h) of the preceding chromato-
graphic step. This means a larger filter area is required per
purification operation and when combined with the multiple
subbatches processed per batch leads to a threefold increase
in virus retention filtration costs, causing the filter costs to
dominate the material costs. The increase in filter costs leads
Figure 5. Contour plots showing the impact of manufacturing
scale and manufacturing strategies on the percentage
difference in cost of goods per gram relative to the
base case scenario for (a) the large-sized company,
(b) the medium-sized company, and (c) the small-
sized company.
(Pre-Clinical, 1 3 0.5 kg; PoC, 1 3 4 kg; Phase III,
4 3 10 kg; Commercial, 20 3 10 kg).
Figure 6. Contour plots showing the impact of manufacturing
scale and manufacturing strategies on (a) the most
economically attractive manufacturing strategies for
each scenario and (b) the resulting manufacturing
cost per launch for all company sizes relative to the
base case manufacturing strategy.
(Pre-Clinical, 1 3 0.5 kg; PoC, 1 3 4 kg; Phase III,
4 3 10 kg; Commercial, 20 3 10 kg).
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to a higher COG/g compared to the corresponding batch-
operated polishing manufacturing strategies, most noticeably
for Commercial manufacture.
The manufacturing cost per launch of a successful drug
candidate (DC) was a key economic metric used to compare
the alternative manufacturing strategies encompassing the
total risk-adjusted clinical development manufacturing cost.
The manufacturing cost per launch captures the costs of all
the unsuccessful DCs incurred alongside the development of
a successfully commercialized DC (10x Pre-Clinical DCs, 7x
PoC DCs, and 2x Phase III DCs). Figure 6b shows the
percentage difference in the cost per launch of a successful
drug candidate for all the alternative manufacturing strate-
gies for all the company scales. The figure highlights how
the FB-CB strategy offers the biggest cost saving (22%) for
a large-sized company. In contrast the ATF-CB or ATF-CC
strategy offers an even bigger cost saving for the small
(40%) and medium-sized (50%) companies, because only
a single manufacturing line is required throughout the clini-
cal phases of development. This allows a much smaller facil-
ity to be used compared to the FB-CB strategy and as the
company size decreases the cost contribution for the indirect
costs increase, allowing the ATF-CB/ATF-CC strategy to
have the cost per launch (small-sized company).
Figure 7 presents a detailed breakdown of the COG/g for
all the alternative manufacturing strategies in a medium-
sized company at the Phase III manufacturing scale. The fig-
ure highlights how the base case and alternative fed-batch
based manufacturing strategies COG/g are dominated by
indirect costs, due to the larger fermentation and purification
capabilities required compared to the smaller highly utilized
ATF perfusion-based strategies. The higher utilization of the
smaller process sequences seen in the ATF perfusion-based
strategies is off-set by the 2.5-fold increase in labour
demand required to operate the continuous capture step for
the duration of the perfusion cell culture. The high labour
demand and multiple production lines seen in the ATF
perfusion-based strategies explains the inability of the strate-
gies to offer a competitive alternative to the base case for
Pre-Clinical manufacture in a large-sized company.
Multiattribute decision-making
This section extends the analysis beyond economic metrics
to include the environmental and operational benefits of each
strategy.
Environmental Impact Analysis. The tool was also used
to capture the water and consumable usage of the alternative
manufacturing strategies to assess the environmental impact
of the strategies across a range of manufacturing and com-
pany scales. E-factor values were derived for the usage of
water (cell culture media, process buffers, CIP buffers, and
rinse water) and consumables (bags, membranes, and resins)
within the manufacturing process. Typical mAb manufactur-
ing strategies (base case) consume water from 3,000 to over
7,000 kg water per kilogram product. The cell culture steps
consume between 20% and 25% of the total, with the chro-
matographic operations often surpassing 50% of the total.43
As expected, all the alternative manufacturing strategies
have a lower water E-Factor value in comparison to the base
case strategy, where the difference in water usage can be
directly related to the use of the continuous capture step and
the resulting lower buffer requirement. Table 6 demonstrates
how the ATF perfusion-based manufacturing strategies have
an even lower water E-factor value than the fed-batch based
strategies. A typical ATF-perfusion process without a contin-
uous capture step has been shown to have higher process
water usage compared to a fed-batch process due to the high
media usage (Pollock et al., 2013a).16 The removal of the
dedicated primary clarification step and the use of the single-
use bioreactors (SUB) by the ATF perfusion process reduces
the nonprocess water usage by 30% (Pollock et al.,
2013a).16 These trends when combined with a continuous
capture step allow the ATF perfusion-based strategies to
reduce their total water usage by 25–45%. In contrast the
Figure 7. A comparison of cost of goods per gram with a
detailed breakdown of material costs on a category
basis for (a) the base case, (b) FB-CB, (c) ATF-CB,
(d) FB-CC, (e) ATF-CC scenario for a Phase III
clinical batch in a medium-sized company.
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manufacturing strategies utilising continuous capture and
polishing (FB-CC, ATF-CC) have higher water E-Factor val-
ues compared to the continuous capture and batch polishing
manufacturing strategies (FB-CB, ATF-CB). The increase in
E-Factor value is due to the higher number of subbatches
processed every batch, causing an increase in CIP buffers
and rinse water used in cleaning between subbatches.
The consumable E-Factor values are highly dependent on
the amount of single-use technologies and resin volume
employed by the strategies. Table 6 highlights how all the
manufacturing strategies have a lower consumable E-Factor
than the base case due to the use of the continuous capture
step reducing the resin volumes used. The ATF perfusion-
based strategies have a lower E-factor value than the fed-
batch based strategies even though they employ SUBs
because this increase in consumable waste is countered by
the 10-fold reduction in resin volume seen.
Operational Risk Analysis. A risk score was assigned to
each manufacturing strategy to assess the operational feasi-
bility with respect to strategy robustness (likelihood of batch
failure). The risk score is a ranking value used to compare
the alternate strategies and does not capture a true value for
batch failure risk. Table 7 shows the risk score for both the
upstream and downstream sections of the manufacturing
strategies. The upstream risk score was calculated by assum-
ing that each addition to the bioreactor had a 1 in 1,000
chance of causing contamination (Pollock et al., 2013b).17
The fed-batch based strategies have a total of ten reactor
additions (initial media fill and nine feeds) and therefore
have a 1% risk score. In contrast the perfusion strategies had
approximately 28 additions due to the daily media exchanges
and therefore have a risk score of 2.8%. A similar approach
was also used for the downstream risk score, where for every
virus retention filtration (VRF) operation there was a 1 in a
1,000 chance of a filter or quality control failure. The same
logic was applied to chromatographic operations where every
cycle there was a 1 in 1,000 chance of a failure event of
which 10% of these would lead to a batch failure. Table 7
demonstrates how the ATF perfusion-based strategies have a
higher risk score for both the upstream and downstream due
to the high number of media exchanges and cycles in the con-
tinuous chromatography capture step. The continuous capture
and polishing based strategies also have high risk scores due
to the numerous VRF operations, resulting in the ATF-CC
strategy having the highest risk score of all the strategies due
to high number of processing operations per batch.
Table 6. E-factor Scores for the Alternative Batch, Continuous and
Hybrid Manufacturing Strategies
Manufacturing
Strategies
Water
(kg/kg product)
Consumable
(kg/kg product)
Base case 3,900–7,250 6–73
FB-CB 3,000–6,400 8–61
ATF-CB 2,150–5,500 6–35
FB-CC 2,750–7,450 13–48
ATF-CC 2,300–5,550 8–25
Table 7. Batch Operational Risk for the Alternative Batch, Continu-
ous, and Hybrid Manufacturing Strategies
Manufacturing
Strategies USP Risk DSP Risk Overall Risk Score
Base case 1% 0.2% 1.2%
FB-CB 1% 0.3% 1.3%
ATF-CB 2.8% 2.3% 5.1%
FB-CC 1% 1% 2%
ATF-CC 2.8% 4.6% 7.4%
Figure 8. Sensitivity spider plots portraying the effect of the
economic attribute combination ratio (R1) in the
overall aggregate scores when the environmental
combination rate is constant (0.1), for (a) the large-
sized company, (b) medium-sized company, and (c)
small-sized company, for the base case (solid black
line), FB-CB (gray dashed line), ATF-CB (gray dot-
ted line), FB-CC (black dashed line), and ATF-CC
(black dotted line).
On the left-hand side of each figure, when the economic attribute
combination ratio is 0.1, the operational attribute combination
ratio is 0.9 and operational benefits are considered more important
in the overall aggregate score. On the right-hand side of each fig-
ure, when the economic attribute combination ratio is 0.9, the
operational attribute combination ratio is 0.1 and economic bene-
fits are considered more important in the overall aggregate score.
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Overall Aggregate Strategy Scores. This section dis-
cusses the results from deriving a single multiattribute score
so as to reconcile any conflicting outputs. The impact of the
relative importance of the economic, environmental, and
operational scores on the ranking of the manufacturing strat-
egies was explored by determining the overall aggregate
strategy score for a range of combination ratios. Figure
8 illustrates the sensitivity of the overall aggregate strategy
scores and hence rank order of the alternative manufacturing
strategies to the economic and operational attribute combina-
tion ratios, for a range of company scales (large, medium,
and small). In this particular scenario, the environmental
attribute combination ratio was set to 0.1. Figure 8a illus-
trates that for a large-sized company the FB-CB is always
the preferred manufacturing strategy regardless how impor-
tant the economic or operational feasibility is ranked. The
ATF perfusion-based manufacturing strategies fail to achieve
a high aggregate score due to their high risk scores and
inability to offer significant economic advantage compared
to the preferred FB-CB manufacturing strategy. In a
medium-sized company (Figure 8b) when the economic ben-
efits are twice as important as the operational benefits
(R1 5 0.6, R3 5 0.3) the ATF-CB and FB-CB strategies are
equally attractive. The ability of the ATF-CB strategy to
offer a superior ranking as the importance of the economic
benefits increases is due to superior savings offered in the
cost per launch and capital expenditure at this company
scale. Figure 8c illustrates how the high importance placed
on capital expenditure and cost per launch by the small-sized
company, results in the ATF-CB becoming the preferred
manufacturing choice with increasing economic importance.
However, if the operational benefits are more important the
FB-CB strategy is still the favoured manufacturing strategy.
When the operational attribute combination ratio is fixed at
0.1 and the environmental attribute combination ratio varied
with the economic attribute combination ratio, the FB-CC
strategy is able to outcompete the FB-CB strategy across all
company scales, because the higher risk score is countered
by the higher significance placed on the lower E-factor rat-
ings. The remaining relationships, with the ATF-CB able to
offer superior ranking as the importance of the economic
benefits increases, are maintained for the medium and small-
sized companies.
Conclusion
This paper has presented a feasibility evaluation of contin-
uous biopharmaceutical manufacturing strategies utilising
perfusion cell culture and semicontinuous chromatography
throughout the product life cycle from Pre-Clinical to Com-
mercial manufacture. The decision-support framework was
configured to cope not only with individual continuous unit
operations but also integrated continuous processes. The
framework enabled a rigorous analysis of the feasibility of
mAb manufacturing facilities based on the standard batch
platform compared to alternative integrated and hybrid con-
tinuous manufacturing strategies across a range of
manufacturing and company scales so as to represent scenar-
ios of relevance to industry. The analysis determined the key
cost contributors in each strategy, as well as the robustness
via an operational risk score and environmental indices that
act as useful E-factor benchmarks for continuous processes.
This enabled the economic, environmental and operational
outputs to be assessed simultaneously. The tool predicts that
the complete continuous strategy (ATF-CC) may find it hard
to compete on economic, environmental and robustness
fronts for Commercial manufacture especially when multiple
trains are required, but offers savings for material supply for
product development stages (Pre-Clinical, PoC, Phase III)
due to the higher productivities and smaller footprint facili-
ties. In contrast, the hybrid batch and continuous strategies
(FB-CB and ATF-CB) outperform the continuous strategy
for all manufacturing and company scales when weighing up
multiple economic, operational and environmental perspec-
tives. The FB-CB strategy was shown to be the most consis-
tent strategy offering savings at all manufacturing and
company scales and is always the preferred manufacturing
strategy for the large-sized company. The ATF-CB strategy
is predicted to offer superior economic benefits for material
supply during product development that outweigh its lower
robustness and increased Commercial manufacturing costs
for the medium and small sized companies as demonstrated
in the multi-attribute analysis. However, the analysis
highlighted that if the operational feasibility is considered
more important than the economic benefits the hybrid FB-
CB strategy is found to be the preferred strategy for all com-
pany scales. This paper demonstrates how the simulation
framework acts as a valuable test bed for assessing the
potential of novel continuous strategies to cope with differ-
ent scales of operation and decisional drivers.
The analysis demonstrates scenarios where continuous
processing can offer COG and operational robustness bene-
fits. Industrial uptake of continuous technologies will also be
affected by further considerations that include the the devel-
opment effort required, technology readiness for large-scale
manufacture (e.g., availability of GMP skids, online analytics
and control, hardware reliability), protocols and training to
deal with the extra operational complexity, and regulatory
concerns.
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